Expansion of healthcare product sales and development of proprietary products
First written in FY2016. 7 of 14 entries say "Advanced", first in FY2018. Latest entry: 2026-08-10.
No other company in this theme has enough history to compare yet.
- FY2025-H1Decline in healthcare product salesAnnual report
「In the Solutions Business, sales of the Digital Colposcope Q-CO declined in the healthcare field. Revenue ¥47 million ¥38 million -17.9% Operating profit (¥146 million) (¥134 million) —」
While the disclosure had previously stated that products such as the Digital Colposcope Q-CO had led sales in the healthcare field, it explicitly noted a decline in sales of that product during the current interim consolidated accounting period. - FY2024-Q2AdvancedAnnual report
「In the healthcare field, the "Electrical Stimulator WILMO" and "Digital Colposcope Q-CO" led sales.」
In addition to the Digital Colposcope Q-CO, which led sales in the previous quarter, the Electrical Stimulator WILMO was also identified as a product contributing to sales in the healthcare field. - FY2024-Q1Digital Colposcope Q-CO drove salesAnnual report
「In the Solutions segment, the healthcare field was led by sales of the "Digital Colposcope Q-CO,"」
The disclosure states that sales in the healthcare field were led by the existing "Digital Colposcope Q-CO," explicitly identifying the product's contribution. - FY2023-Q3RestatedAnnual report
「In the Solutions Business, sales in the RFID field declined, but sales in the healthcare field increased, resulting in higher segment revenue.」
Healthcare sales continued to increase and contributed to Solutions Business revenue growth despite the decline in RFID sales. - FY2023-Q2RestatedAnnual report
「In the Solutions Business, sales in the healthcare field increased, but」
Healthcare sales continued to increase but were insufficient to offset the decline in RFID sales, resulting in lower revenue for the Solutions Business as a whole. - FY2023-Q1Increase in healthcare salesAnnual report
「In the Solutions Business, sales in the healthcare field increased, but sales in the RFID field declined. As a result, revenue decreased, while operating profit declined partly because costs incurred to establish a new revenue base increased.」
Although sales in the healthcare field increased, the Solutions Business as a whole recorded lower revenue and profit due to lower RFID sales and higher costs incurred to establish a new revenue base. - FY2022AdvancedAnnual report
「In the healthcare field, we are working to expand sales of the Digital Colposcope Q-CO and WILMO electrical stimulation device. For WILMO, we will also seek to obtain regulatory approval in China, following Japan and Taiwan.」
In addition to expanding healthcare product sales, a new plan was specified to seek regulatory approval for WILMO in China. - FY2021RestatedAnnual report
「In the healthcare field, we expanded our product lineup and conducted research and development aimed at launching new products.」
The company continues to expand its healthcare product lineup and conduct research and development aimed at launching new products. - FY2020AdvancedAnnual report
「As a new product, we developed the Digital Colposcope Q-CO, a medical device used for cervical cancer screening and other procedures.」
The company developed a new medical device in the healthcare field, with the corporate history also recording the start of sales in September 2020. - FY2019AdvancedAnnual report
「In the healthcare field, we began selling the Balance Tutor treadmill system, an active extension, flexion, and rotational exercise device, while conducting research and development to expand our product lineup and launch new proprietary products.」
The company reported concrete progress toward commercialization of healthcare products through the launch of sales of the Balance Tutor treadmill system. - FY2018AdvancedAnnual report
「We began selling Carbon Hand for independence support, an improved version of the SEM Glove for independence support rehabilitation aid, while conducting research and development to expand our product lineup and launch new proprietary products.」
In line with the policy of expanding healthcare product sales and developing proprietary products, the company began sales of an improved product and conducted research and development to expand its product lineup and launch new products. - FY2016First statedAnnual report
「Going forward, we will expand sales of these products while continuing to develop additional proprietary products.」
The company plans to expand sales of rehabilitation aids and medical devices and develop additional proprietary products.